Get started
Author

Noritaka Furuya

Observed name: Furuya, Noritaka
Observed institutions: Tokyo Institute of Technology, Osaka Prefecture University, Kanagawa Children's Medical Center, Kissei Pharmaceutical (Japan), Saitama Citizens Medical Center, The University of Tokyo
ORCID: 0000-0002-6815-479X
Observed ORCID: 0000-0002-6815-479X
OpenAlex ID: A5043166603
Mg2+‐dependent gating of bacterial MgtE channel underlies Mg2+ homeostasis
2009 · Motoyuki Hattori, Norihiko Iwase, et al. · The EMBO Journal · 111
PDF
Structural Basis for the Counter-Transport Mechanism of a H + /Ca 2+ Exchanger
2013 · Tomohiro Nishizawa, Satomi Kita, et al. · Science · 93
A new case of GABA transaminase deficiency facilitated by proton MR spectroscopy
2010 · Megumi Tsuji, Noriko Aida, et al. · Journal of Inherited Metabolic Disease · 70
Mg 2+ -sensing mechanism of Mg 2+ transporter MgtE probed by molecular dynamics study
2008 · Ryuichiro Ishitani, Yuji Sugita, et al. · Proceedings of the National Academy of Sciences · 66
Pure duplication of 19p13.3
2013 · Aki Ishikawa, Keisuke Enomoto, et al. · American Journal of Medical Genetics Part A · 50
Expression analysis of a 17p terminal deletion, including YWHAE, but not PAFAH1B1, associated with normal brain structure on MRI in a young girl
2012 · Keisuke Enomoto, Yasuhiro Kishitani, et al. · American Journal of Medical Genetics Part A · 39
Further delineation of 9q22 deletion syndrome associated with basal cell nevus (Gorlin) syndrome: Report of two cases and review of the literature
2009 · Kayono Yamamoto, Hiroshi Yoshihashi, et al. · Congenital Anomalies · 36
The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity
2017 · Noritaka Furuya, Takaki Momose, et al. · Bioorganic & Medicinal Chemistry Letters · 34
1p36 deletion syndrome associated with Prader–Willi‐like phenotype
2010 · Yu Tsuyusaki, Hiroshi Yoshihashi, et al. · Pediatrics International · 32
Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
2018 · Akihiro Nishiyama, Tadaaki Yamada, et al. · Clinical Cancer Research · 26
5,10-Methylenetetrahydrofolate reductase deficiency with progressive polyneuropathy in an infant
2010 · Megumi Tsuji, Atsushi Takagi, et al. · Brain and Development · 23
Fetal outcome of trisomy 18 diagnosed after 22 weeks of gestation: Experience of 123 cases at a single perinatal center
2015 · Hiromi Nagase, Hiroshi Ishikawa, et al. · Congenital Anomalies · 18
Synthesis and structure–activity relationships of 1-benzylindane derivatives as selective agonists for estrogen receptor beta
2016 · Shigeru Yonekubo, Nobuhiko Fushimi, et al. · Bioorganic & Medicinal Chemistry · 17
Proportion of malformations and genetic disorders among cases encountered at a high-care unit in a children’s hospital
2011 · Akiko Soneda, Hideki Teruya, et al. · European Journal of Pediatrics · 15
Evaluating the correlation of binding affinities between isothermal titration calorimetry and fragment molecular orbital method of estrogen receptor beta with diarylpropionitrile (DPN) or DPN derivatives
2022 · Chiaki Handa, Yuki Yamazaki, et al. · The Journal of Steroid Biochemistry and Molecular Biology · 12
An isoform-selective inhibitor of tropomyosin receptor kinase A behaves as molecular glue
2019 · Noritaka Furuya, Takaki Momose, et al. · Bioorganic & Medicinal Chemistry Letters · 5
Fragment-Based Discovery of an Oral Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of Migraine
2025 · Naohide Morita, Noritaka Furuya, et al. · Journal of Medicinal Chemistry · 2
Spastic quadriplegia in Down syndrome with congenital duodenal stenosis/atresia
2012 · Kenji Kurosawa, Keisuke Enomoto, et al. · Congenital Anomalies · 1
Sup. Figure 6: TRK-A with G595R mutation caused steric hindrance to foretinib. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
2023 · Akihiro Nishiyama, Tadaaki Yamada, et al.
PDF
Sup. Figure 2: KM12SM-ER cells were resistant to treatment with 15mg/kg and 30mg/kg entrectinib in the brain metastasis-mimicking model. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
2023 · Akihiro Nishiyama, Tadaaki Yamada, et al.
Sup. Figure 4: Foretinib and nintedanib inhibited p TRK-A in KM12SM-ER cells more efficiently than that in KM12SM cells. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
2023 · Akihiro Nishiyama, Tadaaki Yamada, et al.
Sup. Figure 5: Entrectinib suppressed phosphorylation of TRK-A with G667C mutation slightly and inhibited phosphorylation of ERK transiently. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
2023 · Akihiro Nishiyama, Tadaaki Yamada, et al.
Sup. Figure 9: Foretinib treatment had no remarkable anti-angiogenic effect in the liver metastasis model or brain metastasis-mimicking model. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
2023 · Akihiro Nishiyama, Tadaaki Yamada, et al.
PDF
Sup. Figure 7: Knockdown of NTRK1 but not of VEGFR-2 or MET inhibited the viability of KM12SM-ER cells in vitro. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
2023 · Akihiro Nishiyama, Tadaaki Yamada, et al.
Sup. Figure 1: EGFP-Eluc gene transfection did not affect the sensitivity of KM12SM cells to entrectinib. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
2023 · Akihiro Nishiyama, Tadaaki Yamada, et al.
Works count: 47
Citation count: 650
H-index: 14
I10-index: 15
Year
Topic
Type